Indeed, circulating PRL levels higher than 100 ng/mL found in patients with prolactinomas or after treatment with hyperprolactinemia-inducing drugs, and in animal hyperprolactinemic models, result in metabolic alterations such as obesity, insulin resistance, non-alcoholic fatty liver disease, and glucose intolerance (57–60). The gene discussed is PRL; the disease is obesity disorder.